JW Pharmaceutical Files Korean Phase 3 Plan for Bofanglutide
JW Pharmaceutical applied to Korea's drug regulator to test the efficacy and safety of once-every-two-weeks bofanglutide in 300 adults with obesity or overweight.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
JW Pharmaceutical filed a Phase 3 clinical trial plan for bofanglutide with Korea's Ministry of Food and Drug Safety on August 18. The candidate is a subcutaneous GLP-1 receptor agonist designed for dosing once every two weeks.
The proposed Korean study would enroll 300 adults with obesity or overweight and compare bofanglutide with placebo for efficacy and safety. JW Pharmaceutical plans to begin the trial in December 2026 and continue it through March 2029.
What JW Pharmaceutical filed
JW Pharmaceutical's application advances bofanglutide toward a Korean Phase 3 trial built around a once-every-two-weeks schedule. The company obtained exclusive Korean development and commercialization rights from China's Gan & Lee Pharmaceuticals in April 2026.
The Korean protocol described in the reports uses placebo as the comparator. Separate overseas clinical development also includes comparisons with existing treatments such as tirzepatide and semaglutide.
Evidence and practical limits
The reported development is a Phase 3 application and planned study, with efficacy and safety designated for evaluation through March 2029. The reports do not supply Korean Phase 3 results from which to estimate treatment response, side effects, or individual variation.
A two-week dosing interval describes the planned schedule, not how any particular person will respond. Decisions about suitability, monitoring, and recovery after possible side effects require an individual assessment by a qualified physician.
Questions for a clinical consultation
When discussing obesity treatment, ask how a GLP-1 receptor agonist would fit your health status and treatment goals. Also consult the physician about what safety monitoring would be appropriate and how side effects would be managed.
Ask what evidence would be needed before considering a once-every-two-weeks option and whether other treatments should be compared. Medication choice should reflect individual variation rather than dosing convenience alone.
Frequently asked questions
How often is bofanglutide designed to be given?
Bofanglutide is being developed as a subcutaneous injection given once every two weeks. That describes the planned regimen; an appropriate treatment schedule would require consultation with a qualified physician.
Who is the planned Korean Phase 3 trial for?
JW Pharmaceutical plans to enroll 300 Korean adults with obesity or overweight. The reports do not state detailed enrollment criteria.
When is the Korean bofanglutide trial planned?
JW Pharmaceutical plans to start the trial in December 2026 and run it through March 2029. The study is intended to evaluate superiority over placebo and safety.
Questions to take to your physician
- Would a GLP-1 receptor agonist be appropriate for my health status and goals?
- What evidence is available for this candidate, and what is still being evaluated?
- What side effects and monitoring should we discuss before treatment?
- How would possible side effects and recovery be managed for me?
- How should a two-week schedule be weighed against other treatment options?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
